Semaglutide-Induced Weight Loss Improves Reproductive Measures in Women with PMOS and Infertility

Infertility, particularly in women with Polycystic Ovary Syndrome (PMOS), is a complex challenge often exacerbated by obesity and insulin resistance. While weight loss is a cornerstone intervention, achieving and sustaining it can be difficult, limiting improvements in reproductive outcomes. GLP-1 receptor agonists like semaglutide are highly effective for weight management, offering a promising pharmacological strategy to address the underlying metabolic dysfunctions and potentially enhance fertility in this population.

This real-world multicenter cohort study investigated the impact of semaglutide pretreatment on reproductive outcomes in women diagnosed with overweight and obesity with infertility, specifically focusing on those with PMOS. Researchers analyzed patient data to correlate weight loss achieved with semaglutide use with various reproductive measures. The observational design aimed to identify associations, comparing outcomes in patients receiving semaglutide as part of their care, implicitly against their baseline or a non-treated cohort, though a direct comparator arm was not explicitly detailed in the abstract.

The study found a clear association between semaglutide-induced weight loss and improved reproductive measures in women with Polycystic Ovary Syndrome (PMOS) who were also overweight or obese with infertility. The primary finding indicates that weight reduction achieved through semaglutide use positively influences key indicators of reproductive health. While specific quantitative data on improvements (e.g., ovulation rates, pregnancy rates, hormonal changes) were not detailed in the abstract, the overall conclusion points to a beneficial effect. This suggests that targeting obesity with GLP-1 receptor agonists may be a viable strategy to enhance fertility outcomes in this patient group, potentially by improving underlying metabolic and hormonal imbalances associated with PMOS. The study highlights a significant link between metabolic improvement via GLP-1R agonism and reproductive function.